Search results
Results from the WOW.Com Content Network
April 1, 2020 at 3:07 PM All Zantac products and generic versions of the heartburn medication should be taken off pharmacy shelves immediately, the Food and Drug Administration announced Wednesday.
Ranitidine, a heartburn medicine sold under the brand name Zantac among others, was pulled from shelves in 2019, [1] following disclosure [2] of potential carcinogenic effects, [3] [4] which its manufacturers were accused of "engaging in a decades-long scheme to conceal." [5] By 2020, the US Food and Drug Administration was telling consumers to ...
The U.S. Food and Drug Administration (FDA) in 2020 pulled Zantac and its generic versions off the market, triggering a wave of lawsuits. The drug, approved over four decades ago, was the world's ...
Delaware's highest court said on Tuesday it will hear an appeal by GSK and other drugmakers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer. GSK ...
The U.S. Food and Drug Administration in 2020 pulled all brands named Zantac and generic versions of the drug off the market, triggering a wave of lawsuits. The drug, approved over four decades ...
The New Haven-based lab said its testing in 2019 revealed that Zantac, also known as ranitidine, could form a cancer-causing carcinogen known as NMDA and was therefore "unfit for human consumption."
In 2020, the U.S. Food and Drug Administration asked drugmakers to pull Zantac and its generic versions off the market after NDMA was found in samples of the drug.
Sanofi acquired Zantac in 2017. Before that, other companies owned the drug. Peter Pitts, the former associate commissioner of the FDA, says these types of lawsuits are concerning for the industry.